This segment focuses on the research and development of novel therapies for dermatological conditions, including eczema, psoriasis, and acne. Research and Development activities include formulation development, preclinical studies, and clinical trials. Technologies and methodologies employed include topical formulations, and potentially, advanced drug delivery systems. The therapeutic areas covered are primarily skin disorders, aiming to improve patient outcomes by reducing symptoms, improving quality of life, and addressing unmet medical needs. Market positioning is centered on providing innovative solutions in a competitive market, with advantages in intellectual property and targeted therapies. Future opportunities include expanding the pipeline and securing regulatory approvals. Clinical trials are a key aspect of this segment, with a focus on safety and efficacy. Partnerships and collaborations are pursued to accelerate development and commercialization.

This segment is dedicated to developing therapies that address the side effects of cancer treatments, specifically focusing on skin toxicities associated with tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. Research and development efforts include the formulation and testing of HT-001, a topical treatment designed to alleviate skin rashes and other dermatological issues. The segment utilizes pharmaceutical formulation technologies and clinical trial methodologies to evaluate the efficacy and safety of its products. The primary therapeutic area is supportive care for cancer patients, aiming to improve their quality of life during treatment. Market positioning involves addressing a significant unmet need in oncology, offering a potential solution to a common and debilitating side effect. Future opportunities include expanding the application of HT-001 to other cancer therapies and securing regulatory approvals. Clinical trials are crucial for demonstrating the effectiveness of HT-001. Partnerships with oncology centers and pharmaceutical companies are essential for clinical trial execution and market access.

This segment focuses on the development of novel therapies for metabolic diseases, including obesity and fatty liver disease. Research and development activities include a strategic 50:50 joint venture with Silo Pharma to develop and commercialize a potential treatment for obesity and metabolic disease. The novel therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor (GDNF), a VA-invented therapy. The segment utilizes pharmaceutical formulation technologies and clinical trial methodologies to evaluate the efficacy and safety of its products. The primary therapeutic area is metabolic diseases, aiming to improve patient outcomes by reducing symptoms, improving quality of life, and addressing unmet medical needs. Market positioning is centered on providing innovative solutions in a competitive market, with advantages in intellectual property and targeted therapies. Future opportunities include expanding the pipeline and securing regulatory approvals. Clinical trials are a key aspect of this segment, with a focus on safety and efficacy. Partnerships and collaborations are pursued to accelerate development and commercialization.